Bolt Biotherapeutics Inc (BOLT) Stock Price, Quote & News

Company Profile

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumor...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 665 9295

Website: www.boltbio.com

Address:

900 Chesapeake Drive, Redwood City, United States

BuyNow_SellLater Apr. 27 at 4:57 PM

$BOLT good day to add here

0 · Reply

SheriffGrover Apr. 25 at 10:30 PM

$BOLT https://www.fiercebiotech.com/biotech/pfizer-ends-work-phase-1-stage-immunostimulatory-drug-conjugate-cancer-patients Thoughts ? TIA

0 · Reply

SheriffGrover Apr. 25 at 9:39 PM

$BOLT https://www.fiercebiotech.com/biotech/compass-usona-score-fda-national-priority-vouchers-amid-trump-administrations-psychedelic

1 · Reply

SuperGreenToday Apr. 22 at 1:19 AM

$BOLT

0 · Reply

Golibajje Apr. 21 at 2:18 PM

$BOLT Cup and handle formation on an upcoming milestone - Phase 1 results in Q3!! Quietly going up!! Major and only player in ISAC treating cancer, targeting $18 billion market!!! Trading at $9.5m mkt cap with $31 million cash!! $ENVB $CMPS

0 · Reply

Golibajje Apr. 20 at 2:20 PM

$BOLT Another one will move like $ENVB. Cup and handle formation for $BOLT ! Pfizer holding shares in 1.9 million float with mkt cap of $9M!! Cash it self is $31 million!! Only isac player targeting cancer 18.2 claudin in the field.. Phase 1 results in Q3!! Trading almost at lower end.. 1/3.5 of cash!!

0 · Reply

Golibajje Apr. 16 at 4:50 AM

$BOLT Cup and handle formation! Watch out

0 · Reply

OfficialStocktwitsUser Apr. 16 at 1:44 AM

$BOLT RSI: 56.59, MACD: 0.0393 Vol: 0.24, MA20: 4.56, MA50: 4.68 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Golibajje Apr. 15 at 10:57 PM

$BOLD Along with this $BOLT is another lottery ticket in the making! It is trading nearly 1/4th of cash (low float with 1.9m shares.. $9M mkt cap vs $31M cash).. they have phase 1 results in Q3.. disruptive treatment in BILLION $$ mkt! Could go 500%+ if the results are positive! $ZNTL $ALMS

1 · Reply

NasdaqPulse Apr. 12 at 8:00 PM

$BOLT LAYOFFS: 1/3 of Workforce Gone! 👉Click to view @NasdaqPulse for timely updates amid the volatility. Massive shake-up at Bolt as the company announces it’s slashing 33% of its workforce. The reason? AI disruption hitting hard. With automation and machine learning taking over more roles, companies are pivoting quickly, and Bolt is no exception. Is this a wake-up call for the sector? Big cuts like these show that even tech giants aren’t immune to the cost-cutting pressure in the age of AI. Investors, how are you seeing this play out? Could this signal more pain for tech stocks focused on traditional models or is it a necessary step for growth? $BOLT's price action already showing signs of weakness... Watch the next few days closely.

1 · Reply

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Feb 24, 2026, 8:00 AM EST - 2 months ago

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Nov 12, 2025, 4:05 PM EST - 6 months ago

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 1, 2025, 4:05 PM EDT - 7 months ago

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Aug 14, 2025, 4:05 PM EDT - 9 months ago

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 5:30 PM EDT - 1 year ago

Bolt Biotherapeutics Transcript: Status Update

May 12, 2025, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:00 AM EDT - 1 year ago

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Mar 24, 2025, 4:20 PM EDT - 1 year ago

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Feb 11, 2025, 4:05 PM EST - 1 year ago

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Nov 7, 2024, 10:00 AM EST - 1 year ago

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Bolt Biotherapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 6, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Bolt Biotherapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Announces Changes to its Board of Directors

Sep 4, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

Sep 2, 2024, 11:11 AM EDT - 1 year ago

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

$Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions$

Sep 2, 2024, 11:00 AM EDT - 1 year ago

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

Aug 31, 2024, 11:25 AM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

$Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm$

Aug 31, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

Aug 29, 2024, 8:49 PM EDT - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investors To Join A Lawsuit For Securities Fraud Against Bolt Biotherapeutics Inc

$A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm$